GLP-1, Clear Protein, and the 2026 Supplement Trends Worth Paying Attention To
Most trend pieces are noise. They list 15 ingredients, predict that wellness will keep growing, and tell you nothing you can act on. This isn’t that.
There are three demand shifts shaping the supplement market in 2026 that genuinely change how a brand should think about its next SKU, plus one supply-side shock that most trend coverage is ignoring entirely, even though it will decide who actually gets to capitalize on the other three. They’re connected by a single thread: the supplement consumer of 2026 looks nothing like the one the category was built for.
If you’re an established brand deciding where your next formulation dollar goes, these are the supplement trends 2026 is rewarding, and, more importantly, what each one means for what you build next.
Trend 1: GLP-1 Is Reshaping the Category, and the Opportunity Isn’t the Drug
The headline numbers get misquoted constantly, so let’s be precise. Current polling puts roughly 1 in 8 US adults on a GLP-1 medication right now, with nearly 1 in 5 having taken one at some point. Usage is highest exactly where supplement spending is strongest: adults 50 to 64, skewing female. Whatever the exact figure on the day you read this, the direction is settled. This is mainstream behavior now, not a niche.
Here’s the move smart brands are making: they’re not chasing the drug. They’re building the support category around it. People on GLP-1s eat substantially less, which means less protein, less fiber, fewer micronutrients, and a documented risk of losing lean muscle alongside fat. Their bodies still need all of those inputs. That gap is the opportunity, and the market is already pricing it: the GLP-1 companion products category is estimated around $4.7 billion in 2025, headed toward roughly $5.2 billion in 2026, with high-protein products expected to be its largest segment at close to a third of the market.
What a credible companion stack looks like is becoming clearer too: high-quality protein for muscle preservation, fiber for digestive support, electrolytes, and high-potency multivitamins that backfill what a reduced diet leaves out. The formulation question worth putting to your R&D partner isn’t “should we do a GLP-1 product.” It’s “what does a companion stack our specific audience would trust actually look like?”
A note on claims, because this category is a minefield: nutrition-support positioning is very different from drug-adjacent disease claims. Any GLP-1 companion product needs its messaging reviewed against FDA structure/function rules, and its formula reviewed by qualified regulatory and formulation professionals, before it goes anywhere near a label.
Trend 2: Clear Protein Is Protein’s Second Act
Protein isn’t a trend; it’s a staple. But the format is having a genuine second act, and it looks nothing like the first one. Clear proteins, built on whey isolate or collagen with a light, juice-like drinking experience, are pulling in consumers who never wanted a thick, chalky shake.
The numbers are real: the clear whey isolate market is tracking from roughly $6.3 billion in 2025 to about $6.7 billion in 2026, and a growing share of new protein launches now feature a clear format. The deeper reason is positioning, not taste. A clear, lightly flavored protein reads more like an enhanced water than a supplement, which removes the identity barrier for the huge share of consumers who want protein but don’t see themselves as gym people. Same nutritional benefit, completely different consumer, different shelf, different marketing.
The catch is manufacturing. Clear protein lives and dies on solubility and clarity. Get it slightly wrong and you get cloudiness, sediment, or a gritty mouthfeel that no marketing budget can fix. The format is approachable for consumers and demanding for R&D, which is exactly why it rewards brands whose manufacturer has handled protein solubility at scale.
And there’s a second catch, big enough to be its own trend.
The Shock: Protein Supply Is the Story Nobody’s Pricing In
Here’s what most 2026 trend coverage leaves out: the two trends above are colliding with a raw material market that can’t keep up.
GLP-1 users need more protein per calorie. Food brands are adding protein to everything from water to candy. Whey production, which is a byproduct of cheesemaking and can’t simply be scaled on demand, hasn’t kept pace. The result, by mid-2026: whey protein concentrate and isolate in critically short supply, some suppliers sold out for the entire year, major buyers locked into forward contracts, and finished protein prices up 50 to 110 percent over 2024 in parts of the market. Most analysts don’t expect meaningful relief until late 2026 at the earliest, with new processing capacity arriving into 2027.
For a brand, this changes the math on both trends above. The winners in GLP-1 companion nutrition and clear protein won’t just be the brands with the best positioning. They’ll be the brands that secured supply. Practically, that means three things.
- Lock sourcing before you lock marketing. A launch plan built on an ingredient you can’t buy is a press release, not a product.
- Pressure-test blends and alternatives early. Whey-plus blends, collagen bases for clear formats, and plant proteins all have trade-offs in taste and performance, and those trade-offs are R&D questions, not procurement footnotes.
- Ask your manufacturer hard questions about their supplier network. Depth of sourcing relationships is suddenly worth more than a marginally better unit price.
Scarcity isn’t only a threat. For established brands with a manufacturer who can actually source, it’s a moat: shelf space vacated by competitors who couldn’t get powder is still shelf space.
Trend 3: From Sports Nutrition to Overall Health
Underneath all of this sits a bigger structural shift. For years, the action in supplements was sports nutrition: performance, pump, recovery, aimed at the gym. That market is still real, but it’s no longer where the growth is.
“It’s around overall health rather than sports nutrition nowadays,” says Michael DeAngelis, Senior Account Executive at NutraStar.
The fastest-growing categories now sit under the banner of healthspan: longevity and healthy aging, cognitive performance, immunity, stress and sleep, and metabolic health. The cellular-health end of this is moving especially fast; industry coverage in 2026 reports the healthy aging and cellular health segment growing at double-digit rates, with NAD+ related products driving much of it. “Longevity” in 2026 isn’t a single hero ingredient. It’s the active maintenance of mobility, cognition, immunity, and recovery, bought by two very different customers: adults over 60 protecting their independence, and 35-to-55 “optimizers” treating aging as a project.
For an established brand, the strategic question is uncomfortable but important: is your positioning still aimed at who your customer was, or at who they are now? A brand still leading with gym-performance messaging may be talking past the wellness consumer who’s actually buying the category in 2026.
The Three-Question Filter Before You Chase Any of This
Trends create FOMO, and FOMO writes bad briefs. Before committing formulation dollars to any of the shifts above, run the idea through three questions.
- Can you source it? Not “does the ingredient exist,” but can you get it, at your volume, on your timeline, at a cost your margin survives? In 2026, this question kills more launches than consumer demand ever will.
- Can you claim it? If the product only sells with messaging your regulatory counsel won’t approve, you don’t have a product. GLP-1 adjacency makes this question existential.
- Can you own it? If your version would be identical to the ten other launches in the category, the trend will happen with or without you. Format, flavor experience, and formulation quality are where differentiation actually lives, and all three are manufacturing questions.
A yes to all three is a brief worth writing. Two yeses is a conversation with your manufacturer. One yes is a trend piece you enjoyed reading.
What This Means for Your 2026 Formulation Strategy
Three demand shifts, one supply shock, one throughline: the supplement buyer has broadened, and the products that win are the ones that meet them where they are, built on supply chains that hold.
- Look at your portfolio through a whole-health lens, not just a performance one. Where does an existing formula extend naturally into metabolic, cognitive, or longevity territory?
- If you’re in protein, evaluate a clear format seriously, and pressure-test both your manufacturer’s solubility track record and their whey sourcing before you commit.
- If you’re considering a GLP-1 companion play, lead with nutrition-support science and get regulatory review early. The opportunity is large; the claims risk is larger.
- Move while the categories are still forming. The brands that win these shifts commit before the trend is obvious to everyone, and in this market, before the raw materials are spoken for.
Where NutraStar Fits
We sit at a useful vantage point on all of this. We don’t sell our own branded supplements. We manufacture for the brands navigating exactly these decisions, which means we see what’s actually moving across hundreds of clients, not just what one brand is betting on. Our R&D teams in Farmingdale, NJ and Chandler, AZ work on protein solubility, companion-nutrition formulations, and whole-health stacks every week, and our ISO 17025-accredited in-house lab means the testing that proves a formula out happens under our own roof. In a supply-constrained year, being fully integrated matters more than usual: sourcing, formulation, testing, and production sit inside one company, so availability problems surface at the feasibility stage, not mid-production.
The trends above aren’t predictions to us. They’re the briefs landing on our formulation team’s desk right now.
Thinking through a 2026 product around any of these shifts? Our team helps brands sanity-check formulation, sourcing, and feasibility every week. No pitch, just a straight conversation.
